Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:BHVN
CUSIPN/A
Phone203-404-0410
Debt
Debt-to-Equity RatioN/A
Current Ratio6.80
Quick Ratio6.80
Price-To-Earnings
Trailing P/E Ratio-6.76
Forward P/E Ratio-5.03
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book9.24
Profitability
EPS (Most Recent Fiscal Year)($5.00)
Net Income$-127,190,000.00
Net MarginsN/A
Return on Equity-137.13%
Return on Assets-120.17%
Miscellaneous
Employees42
Outstanding Shares38,880,000
Market Cap$1.31 billion
Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions
What is Biohaven Pharmaceutical's stock symbol?
Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
How were Biohaven Pharmaceutical's earnings last quarter?
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) issued its quarterly earnings results on Tuesday, May, 15th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.12) by $1.21. View Biohaven Pharmaceutical's Earnings History.
When is Biohaven Pharmaceutical's next earnings date?
What price target have analysts set for BHVN?
7 brokerages have issued 1-year price targets for Biohaven Pharmaceutical's stock. Their predictions range from $40.00 to $50.00. On average, they expect Biohaven Pharmaceutical's share price to reach $45.00 in the next year. This suggests a possible upside of 35.8% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.
What is the consensus analysts' recommendation for Biohaven Pharmaceutical?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.
What are Wall Street analysts saying about Biohaven Pharmaceutical stock?
Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (8/14/2018)
- 2. Cantor Fitzgerald analysts commented, ": Following our meeting with CEO Vlad Coric and CFO Jim Engelhart earlier this week, we reaffirm our Overweight rating on BHVN stock, and are increasing our 12-month price target to $50, from $42, driven by multiple expansion. We think the Street’s focus on rimegepant acute oral CGRP data has led to an under-appreciation of Biohaven’s other opportunities to drive long term share holder value beyond current levels. The takeaways from our meeting are detailed below and underscore our belief BHVN shares remain undervalued at current levels." (7/12/2018)
- 3. Canaccord Genuity analysts commented, "We await more details on the atogepant data. That said, we believe these early results bode well for the use of the oral anti-CGRP approach towards migraine prevention, as the data appear to hold their own against the competing injectable anti-CGRP biotech approach. At this time, our BHVN model and DCF-based price target of $40 continue to include no value for BHV-3500. These atogepant data, however, make us more optimistic that BHV-3500 could generate positive data as well over time, and we are reiterating our BUY rating on BHVN. Early days, but atogepant appears to hold its own vs. injectable products It is still very early and atogepant is yet to work in a full pivotal program." (6/11/2018)
- 4. Needham & Company LLC analysts commented, "Biohaven released financial results yesterday and we spoke w/ mgmt for an update. Top-line results from remaining Phase 3 Migraine trials of rimegepant (1-year safety trial and orally disintegrating tablet [ODT] trial) are still expected 4Q18. We expect data from these trials as well as from the ubrogepant open-label long-term extension trial later this yr to provide a more complete picture of safety and efficacy profiles. We currently view both the Biohaven and Allergan drugs as competitive, but acknowledge lower pain figures for rimegepant at 2hrs after administration. Mgmt is exploring partnership options for rimegepant, although we currently assume in our model that the drug will be commercialized by Biohaven. Reiterate BUY." (5/16/2018)
Who are some of Biohaven Pharmaceutical's key competitors?
Some companies that are related to Biohaven Pharmaceutical include Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY) and Opko Health (OPK).
Who are Biohaven Pharmaceutical's key executives?
Biohaven Pharmaceutical's management team includes the folowing people:
- Dr. Vladimir Coric, CEO & Director (Age 47)
- Mr. James Engelhart, Chief Financial Officer (Age 54)
- Dr. Charles Conway, Chief Scientific Officer (Age 56)
- Dr. Robert Berman, Chief Medical Officer (Age 55)
- Mr. John Tilton, Chief Commercial Officer (Age 50)
When did Biohaven Pharmaceutical IPO?
(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
Has Biohaven Pharmaceutical been receiving favorable news coverage?
News stories about BHVN stock have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biohaven Pharmaceutical earned a news impact score of 0.09 on Accern's scale. They also gave news articles about the company an impact score of 45.86 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Biohaven Pharmaceutical.
Who are Biohaven Pharmaceutical's major shareholders?
Biohaven Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (8.49%), BlackRock Inc. (5.38%), VHCP Management II LLC (3.64%), FMR LLC (3.48%), Eagle Asset Management Inc. (2.62%) and Emerald Advisers Inc. PA (1.04%). Company insiders that own Biohaven Pharmaceutical stock include Albert Cha, Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.
Which major investors are selling Biohaven Pharmaceutical stock?
BHVN stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Eagle Asset Management Inc., Sigma Planning Corp and Rhumbline Advisers. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.
Which major investors are buying Biohaven Pharmaceutical stock?
BHVN stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Schwab Charles Investment Management Inc., Emerald Advisers Inc. PA, Bank of America Corp DE, VHCP Management II LLC, DAFNA Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Albert Cha, James Engelhart and Robert Berman. View Insider Buying and Selling for Biohaven Pharmaceutical.
How do I buy shares of Biohaven Pharmaceutical?
Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biohaven Pharmaceutical's stock price today?
One share of BHVN stock can currently be purchased for approximately $33.13.
How big of a company is Biohaven Pharmaceutical?
Biohaven Pharmaceutical has a market capitalization of $1.31 billion. The company earns $-127,190,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Biohaven Pharmaceutical employs 42 workers across the globe.
How can I contact Biohaven Pharmaceutical?
Biohaven Pharmaceutical's mailing address is 234 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.
MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
